Oncternal Therapeutics Analysis
Oncternal Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Oncternal Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Oncternal Therapeutics is worth, separate from its market price. There are two main types of Oncternal Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Oncternal Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Oncternal Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Oncternal Stock trading window is adjusted to America/New York timezone.
Oncternal |
Oncternal Stock Analysis Notes
The company has price-to-book ratio of 0.17. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncternal Therapeutics recorded a loss per share of 11.69. The entity last dividend was issued on the 10th of June 2019. The firm had 1:20 split on the 8th of January 2024. Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. Oncternal Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Oncternal Therapeutics contact the company at 858 434 1113 or learn more at https://www.oncternal.com.Oncternal Therapeutics Investment Alerts
| Oncternal Therapeutics is not yet fully synchronised with the market data | |
| Oncternal Therapeutics has some characteristics of a very speculative penny stock | |
| Oncternal Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M). | |
| Oncternal Therapeutics currently holds about 78.9 M in cash with (32.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.48. |
Oncternal Therapeutics Upcoming and Recent Events
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Oncternal Therapeutics Thematic Classifications
In addition to having Oncternal Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Health ManagementHealthcare providers, hospitals | |
 | BiotechBiotechnology and pharmaceuticals production and services |
Oncternal Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.56 M.Oncternal Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncternal Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncternal Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oncternal Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oncternal Therapeutics Outstanding Bonds
Oncternal Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncternal Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncternal bonds can be classified according to their maturity, which is the date when Oncternal Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US68233JBV52 Corp BondUS68233JBV52 | View | |
| US68233JBU79 Corp BondUS68233JBU79 | View | |
| US68233JBR41 Corp BondUS68233JBR41 | View | |
| US68233JBP84 Corp BondUS68233JBP84 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBG85 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBH68 | View | |
| US68233JBD54 Corp BondUS68233JBD54 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Oncternal Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |